NCT06406140View on ClinicalTrials.gov

Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

January 15, 2026

Study Completion Date

February 15, 2026

Conditions
End-stage Renal Disease
Interventions
DRUG

Niacin tablets 500 mg

tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis

Trial Locations (1)

Unknown

Al Azhar University, Cairo

All Listed Sponsors
lead

Al-Azhar University

OTHER